Search the Newsreel

Number of shareholders of Estrella Immunopharma, Inc. – NASDAQ:ESLAW

This article from TradingView is a placeholder or an incomplete data point regarding the number of shareholders for Estrella Immunopharma, Inc. (NASDAQ: ESLAW). It currently shows no specific shareholder data, indicating that the information is either unavailable or has not yet been populated for …

Scinai Immunotherapeutics Ltd (SCNI) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Scinai Immunotherapeutics Ltd (SCNI), noting its current score of 1.75 and ranking within the Biotechnology & Medical Research industry. It highlights the company's beta value of 2.09, indicating high volatility relative to the S&P 500 index. The …

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

Shares of MoonLake Immunotherapeutics (MLTX) have gained 0.2% over the past four weeks to close the last trading session at $18.99, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. …

Mizuho Lifts Price Target on Immunocore Holdings to $35 From $34, Keeps Neutral Rating

Mizuho has increased its price target for Immunocore Holdings (IMCR) to $35 from $34, while maintaining a Neutral rating on the stock. This adjustment reflects a modest positive outlook from the firm regarding the biopharmaceutical company's valuation.

AC Immune SA (ACIU) Financial Health: Profitability & Balance Sheet Analysis

AC Immune SA (ACIU) has a weak financial status and low operating efficiency, ranking 351 out of 384 in the Biotechnology & Medical Research industry with a financial score of 5.50. Despite this, its latest quarterly revenue increased by 19.51% year-over-year to $1.43 million, …

Altimmune Inc Today's Market Trends | ALT Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

This article provides a detailed analysis of Altimmune Inc (ALT) stock, highlighting its market trends, real-time quotes, and trading strategies. It covers key financial figures, institutional ownership, analyst ratings, and the company's biopharmaceutical pipeline, including pemvidutide for obesity and MASH. Despite recent stock performance, …

ImmuCell Corp (ICCC) Financial Health: Profitability & Balance Sheet Analysis

ImmuCell Corp (ICCC) has a stable financial status with a current score of 8.98, ranking it 17th out of 155 in the Pharmaceuticals industry. The company demonstrated high operating efficiency with its latest quarterly revenue increasing by 28.39% year-over-year to $10.36M, and net profit …

IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease

ImmunityBio (IBRX) stock jumped nearly 8% after the UAE granted its cancer immunotherapy, Anktiva, its broadest approval yet for bladder and metastatic lung cancer. This approval covers a wider range of bladder cancer patients than currently allowed in the U.S. and follows founder Patrick …

Immunome Inc (IMNM) Valuation: PE, PB & Fair Value Analysis

Immunome Inc (IMNM) currently has a valuation score of 8.36, placing it 136th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -9.69, which is significantly below its recent high and slightly above its recent low. Key …

Why (IMVT) Price Action Is Critical for Tactical Trading

This article provides a critical analysis of Immunovant Inc. (IMVT) stock's price action for tactical trading, highlighting neutral near and mid-term readings but a positive long-term bias. It outlines distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. …

(IMNM) Volatility Zones as Tactical Triggers

This article analyzes Immunome Inc. (NASDAQ: IMNM), identifying a mid-channel oscillation pattern and a strong risk-reward short setup. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report also notes a …

Trading the Move, Not the Narrative: (IMCR) Edition

This article analyzes Immunocore Holdings Plc (NASDAQ: IMCR), highlighting a near-term weak sentiment that could test mid-term strength within a broader long-term weak bias. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different …

ImmunityBio receives UAE marketing authorizations for ANKTIVA across NMIBC and NSCLC

ImmunityBio (IBRX) has been granted marketing authorization in the UAE for its cancer drug ANKTIVA for two indications: BCG-unresponsive NMIBC and checkpoint-refractory metastatic NSCLC. This expands ANKTIVA's approvals to 34 countries, with the NMIBC approval being the first worldwide to cover CIS with/without papillary …

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

ImmunityBio's ANKTIVA has received its broadest approval yet in the UAE for non-muscle invasive bladder cancer (NMIBC), covering the entire disease spectrum, and also for metastatic non-small cell lung cancer (NSCLC). This approval marks the fifth jurisdiction to greenlight ANKTIVA, expanding its global reach …

ImmunityBio Gains After UAE Approves ANKTIVA for Bladder and Lung Cancer Treatments

ImmunityBio (NASDAQ:IBRX) shares rose 7.5% after the United Arab Emirates approved its drug ANKTIVA for two cancer indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's international reach to 34 countries and is a significant milestone in …

Immunocore to Detail Its Business and Portfolio on Aug. 6

Immunocore (NASDAQ: IMCR) will release its second-quarter 2026 financial results on Thursday, August 6, 2026, for the period ending June 30, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EDT to discuss the results and provide updates on its …

Immutep's IMP761 Shows Immune Activity in First-in-Human Trial

Immutep (NASDAQ: IMMP) released its Q4 FY26 activities report, detailing new clinical, intellectual property, and financial developments. Key highlights include positive pooled analysis from efti trials showing a 7.7-month median overall survival benefit for biological responders and promising first-in-human data for IMP761, which met …

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

Immunocore Holdings plc (Nasdaq: IMCR) announced it will report its financial results for the second quarter ended June 30, 2026, on Thursday, August 6, 2026. Following the announcement, the company will host a live teleconference and webcast at 8:00 AM ET to discuss these …

Immunocore Holdings PLC (IMCR) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Immunocore Holdings PLC (IMCR), noting its current valuation score of 9.63, ranking 13th in the Pharmaceuticals industry. The company's P/E ratio is -60.75, which is significantly below its recent high and above its recent low. Key valuation …

ImmunityBio stock jumps on UAE drug approval for ANKTIVA

ImmunityBio's shares rose 7.5% after the United Arab Emirates approved its drug ANKTIVA for two indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's global regulatory footprint to 34 countries and is the first worldwide approval for …

Immunome Inc. (IMNM) Q1 2026 Earnings: EPS Beat Estimate as Company Advances Pipeline - Profit Guidance Range

IMUX Q1 2026 Earnings: EPS Miss Widens as Clinical Development Continues - Revenue Growth Report

Immuneering Corporation (IMRX) Q1 2026 Earnings: EPS Beats Estimates Amid Pre-Revenue Phase - Annual Financial Report

Immunovant (IMVT) Projected to Announce Earnings on Thursday

IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035

Immunocore (IMCR) Projected to Release Quarterly Earnings on Thursday

Lyell Immunopharma Inc (LYEL) Risk Assessment: Volatility, Financial Risk & Investment Risk

Lyell Immunopharma Inc (LYEL) has a current risk assessment score of 2.20, ranking 230 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of -0.09 suggests it tends to underperform during market uptrends but experiences smaller declines during downtrends. …

Dow, S&P 500, Nasdaq Futures Rise As Investors Shrug Off Fed Hold, Big Tech Earnings: IBRX, MSFT, SOFI, META In Focus

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

ImmunityBio announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA across two indications: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). This marks the fifth regulatory approval for ANKTIVA …

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma announced the activation of Baylor Scott & White Research Institute as the second clinical site for its Phase I/II STARLIGHT-1 trial. This trial evaluates EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). The expansion …

ImmuCell Corporation Revenue Breakdown – NASDAQ:ICCC

Estrella Immunopharma, Inc. Revenue Breakdown – NASDAQ:ESLAW

This article provides a basic overview of Estrella Immunopharma, Inc. (NASDAQ: ESLAW) financial information available on TradingView, focusing on its revenue breakdown. It indicates that further details regarding segment and regional performance by source and country can be accessed through the platform. The content …

H.C. Wainwright reiterates Altimmune stock rating on trial results

H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for Altimmune (NASDAQ:ALT) following positive Phase 2 trial results for its drug candidate, pemvidutide, in treating alcohol use disorder. The drug met its primary endpoint by significantly reducing heavy drinking days and …

Estrella activates second site for EB103 lymphoma trial By Investing.com

Estrella Immunopharma, Inc. has activated a second clinical site, Baylor Scott & White Research Institute, for its STARLIGHT-1 Phase I/II trial evaluating EB103 for relapsed or refractory B-cell non-Hodgkin’s lymphoma. This expansion aims to broaden the trial's reach and gather more data to determine …

Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Estrella Immunopharma Inc (ESLA), focusing on its PE, PB, and fair value. It includes current stock performance metrics and links to further financial data and company overviews.

Enterprise value to revenue forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL